Diagnosing and managing diabetic somatic and autonomic neuropathy

Shazli Azmi, Maryam Ferdousi, Alise Kalteniece, Hamad Al-Muhannadi, Abdulrahman Al-Mohamedi, Nebras H. Hadid, Salah Mahmoud, Harun A. Bhat, Hoda Y.A. Gad, Adnan Khan, Georgios Ponirakis, Ioannis N. Petropoulos, Uazman Alam, Rayaz A. Malik

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

The diagnosis and management of diabetic neuropathy can be a major challenge. Late diagnosis contributes to significant morbidity in the form of painful diabetic neuropathy, foot ulceration, amputation, and increased mortality. Both hyperglycaemia and cardiovascular risk factors are implicated in the development of somatic and autonomic neuropathy and an improvement in these risk factors can reduce their rate of development and progression. There are currently no US Food and Drug Administration (FDA)-approved disease-modifying treatments for either somatic or autonomic neuropathy, as a consequence of multiple failed phase III clinical trials. While this may be partly attributed to premature translation, there are major shortcomings in trial design and outcome measures. There are a limited number of partially effective FDA-approved treatments for the symptomatic relief of painful diabetic neuropathy and autonomic neuropathy.

Original languageEnglish
JournalTherapeutic Advances in Endocrinology and Metabolism
Volume10
DOIs
Publication statusPublished - 1 Jan 2019

Fingerprint

Diabetic Neuropathies
United States Food and Drug Administration
Phase III Clinical Trials
Diabetic Foot
Delayed Diagnosis
Amputation
Hyperglycemia
Outcome Assessment (Health Care)
Morbidity
Mortality
Therapeutics

Keywords

  • autonomic neuropathy
  • diabetic neuropathy
  • diagnosis
  • treatment

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism

Cite this

Diagnosing and managing diabetic somatic and autonomic neuropathy. / Azmi, Shazli; Ferdousi, Maryam; Kalteniece, Alise; Al-Muhannadi, Hamad; Al-Mohamedi, Abdulrahman; Hadid, Nebras H.; Mahmoud, Salah; Bhat, Harun A.; Gad, Hoda Y.A.; Khan, Adnan; Ponirakis, Georgios; Petropoulos, Ioannis N.; Alam, Uazman; Malik, Rayaz A.

In: Therapeutic Advances in Endocrinology and Metabolism, Vol. 10, 01.01.2019.

Research output: Contribution to journalReview article

Azmi, S, Ferdousi, M, Kalteniece, A, Al-Muhannadi, H, Al-Mohamedi, A, Hadid, NH, Mahmoud, S, Bhat, HA, Gad, HYA, Khan, A, Ponirakis, G, Petropoulos, IN, Alam, U & Malik, RA 2019, 'Diagnosing and managing diabetic somatic and autonomic neuropathy', Therapeutic Advances in Endocrinology and Metabolism, vol. 10. https://doi.org/10.1177/2042018819826890
Azmi, Shazli ; Ferdousi, Maryam ; Kalteniece, Alise ; Al-Muhannadi, Hamad ; Al-Mohamedi, Abdulrahman ; Hadid, Nebras H. ; Mahmoud, Salah ; Bhat, Harun A. ; Gad, Hoda Y.A. ; Khan, Adnan ; Ponirakis, Georgios ; Petropoulos, Ioannis N. ; Alam, Uazman ; Malik, Rayaz A. / Diagnosing and managing diabetic somatic and autonomic neuropathy. In: Therapeutic Advances in Endocrinology and Metabolism. 2019 ; Vol. 10.
@article{fd78340296874c2ba64faf53e52b1a86,
title = "Diagnosing and managing diabetic somatic and autonomic neuropathy",
abstract = "The diagnosis and management of diabetic neuropathy can be a major challenge. Late diagnosis contributes to significant morbidity in the form of painful diabetic neuropathy, foot ulceration, amputation, and increased mortality. Both hyperglycaemia and cardiovascular risk factors are implicated in the development of somatic and autonomic neuropathy and an improvement in these risk factors can reduce their rate of development and progression. There are currently no US Food and Drug Administration (FDA)-approved disease-modifying treatments for either somatic or autonomic neuropathy, as a consequence of multiple failed phase III clinical trials. While this may be partly attributed to premature translation, there are major shortcomings in trial design and outcome measures. There are a limited number of partially effective FDA-approved treatments for the symptomatic relief of painful diabetic neuropathy and autonomic neuropathy.",
keywords = "autonomic neuropathy, diabetic neuropathy, diagnosis, treatment",
author = "Shazli Azmi and Maryam Ferdousi and Alise Kalteniece and Hamad Al-Muhannadi and Abdulrahman Al-Mohamedi and Hadid, {Nebras H.} and Salah Mahmoud and Bhat, {Harun A.} and Gad, {Hoda Y.A.} and Adnan Khan and Georgios Ponirakis and Petropoulos, {Ioannis N.} and Uazman Alam and Malik, {Rayaz A.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1177/2042018819826890",
language = "English",
volume = "10",
journal = "Therapeutic Advances in Endocrinology and Metabolism",
issn = "2042-0188",
publisher = "Sage Periodicals Press",

}

TY - JOUR

T1 - Diagnosing and managing diabetic somatic and autonomic neuropathy

AU - Azmi, Shazli

AU - Ferdousi, Maryam

AU - Kalteniece, Alise

AU - Al-Muhannadi, Hamad

AU - Al-Mohamedi, Abdulrahman

AU - Hadid, Nebras H.

AU - Mahmoud, Salah

AU - Bhat, Harun A.

AU - Gad, Hoda Y.A.

AU - Khan, Adnan

AU - Ponirakis, Georgios

AU - Petropoulos, Ioannis N.

AU - Alam, Uazman

AU - Malik, Rayaz A.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - The diagnosis and management of diabetic neuropathy can be a major challenge. Late diagnosis contributes to significant morbidity in the form of painful diabetic neuropathy, foot ulceration, amputation, and increased mortality. Both hyperglycaemia and cardiovascular risk factors are implicated in the development of somatic and autonomic neuropathy and an improvement in these risk factors can reduce their rate of development and progression. There are currently no US Food and Drug Administration (FDA)-approved disease-modifying treatments for either somatic or autonomic neuropathy, as a consequence of multiple failed phase III clinical trials. While this may be partly attributed to premature translation, there are major shortcomings in trial design and outcome measures. There are a limited number of partially effective FDA-approved treatments for the symptomatic relief of painful diabetic neuropathy and autonomic neuropathy.

AB - The diagnosis and management of diabetic neuropathy can be a major challenge. Late diagnosis contributes to significant morbidity in the form of painful diabetic neuropathy, foot ulceration, amputation, and increased mortality. Both hyperglycaemia and cardiovascular risk factors are implicated in the development of somatic and autonomic neuropathy and an improvement in these risk factors can reduce their rate of development and progression. There are currently no US Food and Drug Administration (FDA)-approved disease-modifying treatments for either somatic or autonomic neuropathy, as a consequence of multiple failed phase III clinical trials. While this may be partly attributed to premature translation, there are major shortcomings in trial design and outcome measures. There are a limited number of partially effective FDA-approved treatments for the symptomatic relief of painful diabetic neuropathy and autonomic neuropathy.

KW - autonomic neuropathy

KW - diabetic neuropathy

KW - diagnosis

KW - treatment

UR - http://www.scopus.com/inward/record.url?scp=85064331741&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064331741&partnerID=8YFLogxK

U2 - 10.1177/2042018819826890

DO - 10.1177/2042018819826890

M3 - Review article

AN - SCOPUS:85064331741

VL - 10

JO - Therapeutic Advances in Endocrinology and Metabolism

JF - Therapeutic Advances in Endocrinology and Metabolism

SN - 2042-0188

ER -